In this white paper, we draw lessons from industries as diverse as food products and toy manufacturing to illustrate how pharmaceutical companies can effectively access innovation outside the traditional in-house R&D model. To read more, click the PDF link below. A version of this article was also published in IN VIVO here.
Potential impact of the CMS GENEROUS model
Reference country selection The model provided guidance on reference countries, defined by the G7 countries plus Denmark and Switzerland. Reference...